The company uses proprietary technology and chemistries to create a strong pipeline of imaging and therapeutic molecules that are highly targeted and optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Founded in 2019 and headquartered in Vancouver, Canada, Alpha9 Theranostics is on the forefront of engineering bespoke radiopharmaceuticals that have the potential to meaningfully extend the lives of patients with favorable safety profiles.